# Pharmaceutical Industry Pain Points

Research 2026-10-17/18. Each pain point lists the evidence quality. "Industry knowledge" means common practitioner experience that this research did **not** independently quantify.

| # | Pain point | Evidence | Pharmodry response (status) |
|---|---|---|---|
| 1 | **Batch release delays** | Paper-based release reported at ~10–40 days; avg. 48 h review per batch report, up to 500 h (BioPharm International/PharmTech article). Older BSM benchmark: ~21 days end-of-manufacture → release (2007, indicative only). | Release-blocker list computed server-side; QA queue; release cycle-time KPI; Command Center SLA exceptions. ✔ |
| 2 | **Paper batch documentation errors** | ~1 error per 100 manual entries (secondary citation, unverified original). | eBMR with limits, required fields, e-signatures, out-of-limit flags, controlled corrections. ✔ basic |
| 3 | **Data integrity findings** | Vendor/webinar summaries: ~15 % of FY2025 FDA drug warning letters cited data integrity, higher for some regions; escalating DI enforcement (Redica). Primary FDA database not analysed. | Hash-chained, append-only audit trail with DB triggers; integrity verification; ALCOA+ capture. ✔ |
| 4 | **Imported API dependence & stock-outs** | ~85–90 % of APIs imported; China ~60–70 %; India 30–40 % of raw materials; 2025 India trade suspension caused emergency measures. | Deterministic stock-cover vs lead-time analytics, FEFO, open-PO awareness, shortage-blocked reservations. ✔ |
| 5 | **Expiry losses** | Industry knowledge. | 30/60/90-day alerts, auto-EXPIRED, projected consumption & recommendations, near-expiry value. ✔ |
| 6 | **OOS investigations & release holds** | FDA 2022 OOS guidance defines phased investigations. | OOS lifecycle, release blocking, deviation/CAPA linkage, QA-only conclusion. ✔ |
| 7 | **CAPA backlogs / repeat failures** | Industry knowledge; Veeva/TrackWise market effectiveness checks as core. | Effectiveness check gating closure, failure KPI, overdue scans, repeat-category trend (Copilot). ✔ |
| 8 | **Supplier qualification** | Industry knowledge; 2024 OPQ report cited (secondary): ~19 % of warning letters linked to offshore API suppliers. | Qualification statuses enforced at PO/GRN, approved materials, scorecards, certificate expiry alerts. ✔ |
| 9 | **Documentation readiness for PIC/S (Pakistan)** | PIC/S Chapter 4 enforced from 25 Feb 2026; SMF/technical agreements from 1 Jun 2026. | Controlled records today; Document management & SMF on roadmap (P3). 🟡 |
| 10 | **Serialization deadline (Pakistan)** | 2D DataMatrix + serials for batches from 9 Oct 2026. | GTIN master data + GS1 batch data string (P2, implemented); serial generation & DRAP reporting roadmap. 🟡 |
| 11 | **Recall readiness / traceability** | GMP expects rapid trace; Pakistani recalls follow DRAP alerts (industry knowledge). | Batch genealogy forward/backward + mock-recall export (P2, implemented). ✔ |
| 12 | **Annual Product Quality Review effort** | PIC/S Ch.1 PQR; Swissmedic interpretation lists contents. | PQR data pack per product/year (P2, implemented). ✔ |
| 13 | **Pharmacovigilance capability gap** | DRAP reports few companies have PV centres. | Out of scope (roadmap). ⬜ |
| 14 | Calibration lapses | Industry knowledge; MES vendors tie calibration to execution. | BLOCK/WARN policy at eBMR step start; alerts. ✔ |
| 15 | Management visibility | Industry knowledge. | Command Center, dashboard drill-down, Copilot. ✔ |

Sources: see `REGULATORY_CONSIDERATIONS.md` and `COMPETITIVE_LANDSCAPE.md`, plus
* BioPharm International — Review by exception: https://www.biopharminternational.com/view/review-exception-connecting-dots-faster-batch-release (accessed 2026-10-18)
* PharmTech — Review by exception: https://www.pharmtech.com/view/review-exception-connecting-dots (accessed 2026-10-18)
* BSM — Lean Batch Records: https://bsmlean.com/sites/default/files/docs/2020-01/BSM_LeanBatchRecords_08uk.pdf (accessed 2026-10-18)
* PharmaNow — FDA warning letter patterns 2025: https://www.pharmanow.live/pharma-events/reading-2025s-fda-warning-letters-the-patterns-reshaping-global-pharma (accessed 2026-10-18; secondary)
* PharmaNow — Regulatory intelligence, warning letters: https://www.pharmanow.live/regulatory-intelligence/fda-warning-letters-pharma-compliance (accessed 2026-10-18; secondary)
